Patents by Inventor Sven Ruf

Sven Ruf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12649750
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Grant
    Filed: September 12, 2025
    Date of Patent: June 9, 2026
    Assignees: Sionna Therapeutics Inc., Genzyme Corporation
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Patent number: 12624051
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Grant
    Filed: September 12, 2025
    Date of Patent: May 12, 2026
    Assignees: Genzyme Corporation, Sionna Therapeutics Inc.
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Publication number: 20260008786
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: September 12, 2025
    Publication date: January 8, 2026
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Publication number: 20260008785
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: September 12, 2025
    Publication date: January 8, 2026
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Publication number: 20250248975
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: August 7, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Publication number: 20250197422
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: June 19, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Publication number: 20250197420
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: June 19, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • Publication number: 20240124408
    Abstract: Compounds of formula (1): wherein R1 represents a —C(R2)(R3)—[C(R4)(R5)]m-L-R6 group or —R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment of oropharyngeal dysphagia.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 18, 2024
    Applicant: Sanofi
    Inventors: Paul Justin Mueller, Florian Auger, Guillaume Begis, Yann Foricher, Christoph Grebner, Stéphane Hourcade, Stéphanie Meyfroot, Sven Ruf, Klaus Wirth
  • Patent number: 9751858
    Abstract: The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: September 5, 2017
    Assignee: SANOFI
    Inventors: Sven Ruf, Josef Pernerstorfer, Thorsten Sadowski, Georg Horstick, Herman Schreuder, Christian Buning, Klaus Wirth
  • Publication number: 20160237060
    Abstract: The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 27, 2016
    Publication date: August 18, 2016
    Inventors: Sven RUF, Josef PERNERSTORFER, Thorsten SADOWSKI, Georg HORSTICK, Herman SCHREUDER, Christian BUNING, Klaus WIRTH
  • Patent number: 9353068
    Abstract: The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: May 31, 2016
    Assignee: SANOFI
    Inventors: Sven Ruf, Josef Pernerstorfer, Thorsten Sadowski, Georg Horstick, Herman Schreuder, Christian Buning, Klaus Wirth
  • Patent number: 9199947
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: December 1, 2015
    Assignee: Sanofi
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Patent number: 9174952
    Abstract: The present invention relates to compounds of the formulae Ia and Ib, wherein G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formulae Ia and Ib, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: November 3, 2015
    Assignee: SANOFI
    Inventors: Sven Ruf, Josef Pernerstorfer, Thorsten Sadowski, Georg Horstick, Herman Schreuder, Christian Buning, Klaus Wirth
  • Patent number: 9150526
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: October 6, 2015
    Assignee: Sanofi
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Patent number: 9120783
    Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, L, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: September 1, 2015
    Assignee: SANOFI
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning
  • Patent number: 9029559
    Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, L, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: May 12, 2015
    Assignee: SANOFI
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning
  • Patent number: 8962671
    Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R11, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: February 24, 2015
    Assignee: Sanofi
    Inventors: Sven Ruf, Thorsten Sadowski, Georg Horstick, Herman Schreuder, Christian Buning, Thomas Olpp, Klaus Wirth
  • Publication number: 20140296296
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Publication number: 20140296239
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Applicant: SANOFI
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Publication number: 20140194445
    Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, L, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 10, 2014
    Publication date: July 10, 2014
    Applicant: SANOFI
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning